- About About
-
Medical
Medical
Medical Patient Resources Cannabis Care Certification Patient's Guide to Medical Cannabis Patient's Guide to CBD Talking to your doctor Become a Legal Medical Marijuana Patient The Medical Cannabis Patient’s Guide for U.S. Travel Guide to Using Medical Cannabis Cannabis Tincture, Salve, Butter and Oil Recipes Arthritis and Medical Cannabis Cancer and Medical Cannabis Chronic Pain and Medical Cannabis Gastrointestinal Disorders and Medical Cannabis HIV/AIDS and Medical Cannabis Movement Disorders and Medical Cannabis Multiple Sclerosis and Medical Cannabis Aging and Medical Cannabis Veterans and Medical Cannabis Medical Marijuana Conditions in Your Area Growing Cannabis Tracking Treatment & Gathering Data with Releaf App Medical Professional Resources Medical Cannabis Continuing Medical Education (CME) Cannabis Safety Medical Cannabis Research
- Legal Legal
-
Advocacy
Advocacy
Advocacy ASA Chapters Start an ASA Chapter Take Action Campaigns No Patient Left Behind End Pain, Not Lives Vote Medical Marijuana Medical Cannabis Advocate's Training Center Resources for Tabling and Lobby Days Strategic Planning Civics 101 Strategic Messaging Citizen Lobbying Participating in Implementation Movement Building Organizing a Demonstration Organizing Turnout for Civic Meetings Public Speaking Media 101 Patient's History of Medical Cannabis
-
Policy
Policy
Policy Policy Positions Model Federal Legislation Download Ending The Federal Conflict Public Comments by ASA Industry Standards Guide to Regulating Industry Standards Recognizing Science using the Data Quality Act Data Quality Act Briefs Fact Sheet on ASA's Data Quality Act Petition to HHS ASA Data Quality Act petition to HHS Information on Lawyers and Named Patients in the Data Quality Act Lawsuit Reports 2021 State of the States Cannabis and Cannabis Resin- Critical Review Preparation Document Medical Cannabis in America
- News News
- Join Join
-
-
Medical Marijuana Group Moves to Hasten Outcome in Federal Lawsuit
San Francisco, CA – A national medical marijuana patients’ rights group filed a motion for summary judgment today in its lawsuit against the federal government in an attempt to accelerate a decision in the case. The plaintiff, Americans for Safe Access (ASA), filed a lawsuit in February 2007 challenging statements by the federal Department of Health and Human Services (HHS) and the Food and Drug Administration (FDA) that marijuana has no accepted medical value.
The lawsuit followed a two-year administrative petition process using a little-known law called the Data Quality Act (DQA), which allows parties to challenge the science used in regulatory policy.
By filing the motion for summary judgment, ASA will force the case to be heard in roughly 90 days. This rare legal move, where judgment is requested from the court before the government has a chance to answer the lawsuit complaint, indicates confidence in the amount of scientific evidence demonstrating marijuana’s medical efficacy. “We are taking an aggressive legal approach for two reasons,” said ASA Chief Counsel Joe Elford. “Not only do we believe we have science on our side, but by quickening the pace with which the federal government recognizes that science,, seriously ill persons who might benefit from medical marijuana will no longer be discouraged from using it.”
The exhibits filed in support of the motion for summary judgment include more than a dozen domestic and international peer-reviewed scientific studies that show the effectiveness of marijuana in treating pain, nausea, muscle spasticity, and many other conditions. The evidence provided by ASA is meant to refute claims by the federal government that “there have been no studies that have scientifically assessed the efficacy of marijuana for any medical condition.” (66 Fed.Reg. 20038, 20052; April 18, 2001.) In addition to the overwhelming evidence, a lack of disputed facts will also help to secure a speedy decision by the court.
The plaintiff’s case was affirmed by a recent editorial in Science Magazine, a publication of the American Association for the Advancement of Science, which posited that HHS had “violated its own DQA guidelines.” The Science editorial followed a February publication by the peer-reviewed journal Neurology of a human trials study in the U.S. clearly showing that marijuana relieved neuropathic pain in people living with HIV/AIDS.
If successful, ASA’s case will be the first in which a court has recognized the necessity of reviewing disputes filed under the DQA. Two other courts have already denied review in lawsuits filed under the Act by large corporations.
Review the Motion for Summary Judgment here.
Review info on the Data Quality Act and ASA’s lawsuit against the federal government here.
With over 30,000 active members in more than 40 states, Americans for Safe Access (ASA) is the largest national member-based organization of patients, medical professionals, scientists and concerned citizens promoting safe and legal access to cannabis for therapeutic use and research. ASA works to overcome political and legal barriers by creating policies that improve access to medical cannabis for patients and researchers through legislation, education, litigation, grassroots actions, advocacy and services for patients and the caregivers.
By filing the motion for summary judgment, ASA will force the case to be heard in roughly 90 days. This rare legal move, where judgment is requested from the court before the government has a chance to answer the lawsuit complaint, indicates confidence in the amount of scientific evidence demonstrating marijuana’s medical efficacy. “We are taking an aggressive legal approach for two reasons,” said ASA Chief Counsel Joe Elford. “Not only do we believe we have science on our side, but by quickening the pace with which the federal government recognizes that science,, seriously ill persons who might benefit from medical marijuana will no longer be discouraged from using it.”
The exhibits filed in support of the motion for summary judgment include more than a dozen domestic and international peer-reviewed scientific studies that show the effectiveness of marijuana in treating pain, nausea, muscle spasticity, and many other conditions. The evidence provided by ASA is meant to refute claims by the federal government that “there have been no studies that have scientifically assessed the efficacy of marijuana for any medical condition.” (66 Fed.Reg. 20038, 20052; April 18, 2001.) In addition to the overwhelming evidence, a lack of disputed facts will also help to secure a speedy decision by the court.
The plaintiff’s case was affirmed by a recent editorial in Science Magazine, a publication of the American Association for the Advancement of Science, which posited that HHS had “violated its own DQA guidelines.” The Science editorial followed a February publication by the peer-reviewed journal Neurology of a human trials study in the U.S. clearly showing that marijuana relieved neuropathic pain in people living with HIV/AIDS.
If successful, ASA’s case will be the first in which a court has recognized the necessity of reviewing disputes filed under the DQA. Two other courts have already denied review in lawsuits filed under the Act by large corporations.
Review the Motion for Summary Judgment here.
Review info on the Data Quality Act and ASA’s lawsuit against the federal government here.
# # #
With over 30,000 active members in more than 40 states, Americans for Safe Access (ASA) is the largest national member-based organization of patients, medical professionals, scientists and concerned citizens promoting safe and legal access to cannabis for therapeutic use and research. ASA works to overcome political and legal barriers by creating policies that improve access to medical cannabis for patients and researchers through legislation, education, litigation, grassroots actions, advocacy and services for patients and the caregivers.
Share